Cravath has represented Johnson & Johnson in connection with the receipt by Ethicon Endo-Surgery, Inc. (“EES”), a Johnson & Johnson company, of an irrevocable, unconditional offer from Devicor Medical Products (“Devicor”), a portfolio company of private equity firm GTCR Golder Rauner, LLC (“GTCR”), to acquire EES’s Breast Care business. The EES Breast Care business sells products designed to help doctors diagnose breast cancer at early stages, while minimizing patient discomfort. The acceptance period for the offer will end on June 15, 2010, unless extended. If the offer is accepted by EES, the proposed transaction will be subject to the fulfillment of certain conditions and would be expected to close by the third quarter of 2010.
The Cravath team includes partners Robert I. Townsend III and Damien R. Zoubek and associates Joseph D. Zavaglia, David J. Perkins and Namsun Kim on corporate matters; partner Eric W. Hilfers and associates Jarrett R. Hoffman and Jared R. Whalen on executive compensation and benefits matters; and partner Andrew W. Needham and associates J. Leonard Teti II and Matthew Cantor on tax matters.